Rédaction Africa Links 24 with Elaine Chen
Published on 2024-04-07 13:45:05
Beta blockers have long been a staple in cardiovascular treatment, particularly in patients who have suffered heart attacks. However, a recent large trial has challenged this practice by suggesting that beta blockers may not provide significant benefits to patients with preserved ejection fraction after a heart attack.
The trial, which included approximately 5,000 patients with preserved ejection fraction, found that long-term treatment with beta blockers did not significantly reduce the combined risk of death or new heart attack. Preserved ejection fraction refers to the heart’s ability to pump blood out of the left ventricle during each heartbeat, with a defined normal range being over 50%.
These findings contradict the widespread use of beta blockers post-heart attack, which is based on outdated research conducted before modern procedures for opening blocked arteries became commonplace. While beta blockers are intended to slow the heart rate and reduce stress on the heart, they can also lead to side effects such as fatigue, weight gain, and sexual dysfunction.
Advancements in medical interventions have resulted in smaller heart attacks with less damage to the heart muscle, prompting a reevaluation of the guidelines recommending beta blockers for all heart attack patients. Observational studies had previously suggested that beta blockers may not be beneficial for individuals with preserved ejection fraction, but until now, there had been a lack of large randomized trials on this topic.
The results of this trial, presented at the American College of Cardiology conference and published in the New England Journal of Medicine, have significant implications for clinical practice. The study followed patients primarily in Sweden, as well as in Estonia and New Zealand, over a median of three-and-a-half years.
While patients taking beta blockers did not experience a statistically significant reduction in the risk of death or new heart attack compared to those not taking the drugs, they also did not have lower risks of individual outcomes like death from any cause, cardiovascular death, heart attack, or hospitalization for heart-related issues. Safety events such as stroke, low blood pressure, and fainting were similar between the two groups.
Subgroup analysis revealed that patients already on beta blockers at the time of a heart attack who continued to take them during the trial had a higher risk of adverse outcomes. However, the researchers attribute this finding to chance rather than a true effect of beta blockers.
Limitations of the study include the lack of a placebo group for patients not taking beta blockers, as well as the predominantly male composition of the study population. The implications of these findings on clinical guidelines and practice remain to be seen, but they challenge long-standing beliefs about the use of beta blockers in post-heart attack care.
Overall, this trial represents a significant step towards reevaluating the role of beta blockers in cardiovascular treatment and highlights the importance of questioning established practices to improve patient outcomes.
